Jan 05, 2023 / 01:55PM GMT
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst
Good morning, and happy new year to everybody. My name is Chris Shibutani. I'm the U.S. large cap pharmaceuticals analyst, and I also cover some of the biotech and biopharma sector. So I was really pleased to see the expectations for performance out of both of those.
Robert M. Davis - Merck & Co., Inc. - CEO & Chairman
Me, too.
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst
Outstanding. We are thrilled to kick off the year. Literally, this is the start of the year, and with Merck being able to be the first voice as the industry and the investor community comes together once again, and we look forward to 2023, where, obviously, expectations for performance there.
Really pleased to have joining with us Rob Davis, CEO, and now Chairman as well, which, I think, is an interesting context. Also our slide should be updated for that. But I also did want to express special thanks to the entire
Merck & Co Inc at Goldman Sachs CEOs Unscripted Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot